Insilico Medicine told investors it expects to be profitable in the first half of 2026, citing revenue momentum tied to collaborations and pipeline progress that includes an AI-developed lead candidate moving into Phase III. In its StockWatch update, the company projected net profit of roughly $33.5 million to $39.5 million for H1 2026. Insilico also projected record first-half revenue of about $102.5 million to $106.5 million, up sharply year over year. The company framed the improvement around its series of partnerships and the maturation of programs reaching later-stage development. Executives highlighted the goal of sustained profitability as it balances discovery revenue with higher-value development revenue as programs scale. The update matters for platform biotechs because it ties financial guidance directly to pipeline stage advancement.